GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » Gross Profit

Suven Pharmaceuticals (BOM:543064) Gross Profit : ₹6,028 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals Gross Profit?

Suven Pharmaceuticals's gross profit for the three months ended in Mar. 2024 was ₹1,300 Mil. Suven Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ₹6,028 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Suven Pharmaceuticals's gross profit for the three months ended in Mar. 2024 was ₹1,300 Mil. Suven Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was ₹2,529 Mil. Therefore, Suven Pharmaceuticals's Gross Margin % for the quarter that ended in Mar. 2024 was 51.39%.

Suven Pharmaceuticals had a gross margin of 51.39% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 6 years, the highest Gross Margin % of Suven Pharmaceuticals was 59.87%. The lowest was 56.26%. And the median was 57.23%.


Suven Pharmaceuticals Gross Profit Historical Data

The historical data trend for Suven Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals Gross Profit Chart

Suven Pharmaceuticals Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
Get a 7-Day Free Trial 4,842.43 5,597.33 7,347.18 7,541.34 6,028.43

Suven Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,116.84 2,140.03 1,441.72 1,146.78 1,299.91

Competitive Comparison of Suven Pharmaceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Suven Pharmaceuticals's Gross Profit falls into.



Suven Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Suven Pharmaceuticals's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=10513.537 - 4485.105
=6,028

Suven Pharmaceuticals's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=2529.303 - 1229.398
=1,300

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,028 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Suven Pharmaceuticals's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=1,300 / 2529.303
=51.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Suven Pharmaceuticals  (BOM:543064) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Suven Pharmaceuticals had a gross margin of 51.39% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Suven Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Pharmaceuticals (BOM:543064) Business Description

Traded in Other Exchanges
Address
3rd Floor, Road No. 5, Avenue 7, Banjara Hills, No. 8-2-334, SDE Serene Chambers, Hyderabad, TG, IND, 500034
Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.

Suven Pharmaceuticals (BOM:543064) Headlines

No Headlines